Quanticate partners with KPS Life to build a unique service offering
A new partnership has been formed this month between Quanticate, the global biometric clinical research organisation, and KPS Life, a global functional service provider offering clinical outsourcing solutions to biopharmaceutical and medical device and diagnostic companies.
The combined expertise of the organisations opens up a broader range of services, that complement each other well, meaning that biotech and pharma companies will have access to biometric data services along with global resourcing solutions.
The companies will also be able to utilise their collective experience to offer end-to-end solutions for pharma companies. This will provide a boost in biopharma companies’ capabilities to run clinical research projects.
“We are thrilled to be partnering with KPS Life and offering biotech and pharma companies access to our expert biometric data services alongside KPS Life’s FSP solutions,” commented David Underwood, CEO at Quanticate.
“By combining our expertise, we will be able to provide an end-to-end solution that delivers high-quality data and comprehensive clinical services to sponsors. This partnership represents a significant milestone for Quanticate and KPS Life, and we look forward to working together to deliver exceptional results for our clients.”
The partnership comes as a strategic move, to provide a unique, well balanced service for biopharma companies, opening up a lot of doors for these companies so they can take advantage of their respective expertise.
“Our clients have come to expect high-quality resource solutions and our deep commitment to solving their staffing challenges in this tough labour environment. We are confident that partnering with Quanticate will be a strong addition to our collective service offerings,” stated David Kelly, CEO at KPS Life.
“This partnership represents an exciting opportunity for Sponsor companies to access a full range of services from two expert organisations. We believe our collaboration will help companies achieve their clinical research goals more efficiently and effectively.”
Related News
-
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Women in Pharma: Marketing for the other half in healthcare
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. This instalment highlights not only the importance of ma... -
News CAR-T therapy for renal cell carcinoma gains fast track approval
Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company. -
News CPHI Podcast Series: The ripple effects of nearshoring in pharma
In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subs... -
News Bringing the pharmaceutical supply chain closer to home
The pharmaceutical supply chain has encountered numerous disruptions in the last few years, impacting procurement, manufacturing, packaging, and distribution operations within the pharmaceutical industry. Read about the rise in calls for near/resh... -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News President Biden's executive order to increase access to contraception
In the USA, President Joe Biden will be signing an executive order to expand access to contraception.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance